New research indicates Ozempic and Mounjaro offer significant cardiovascular benefits beyond weight loss and blood sugar control. A real-world study...
Vous n'êtes pas connecté
Maroc - ABUDHABIMAGAZINE.AE - A La Une - 12/Nov 16:03
New research from the Technical University of Munich and Harvard Medical School reveals that popular GLP-1-based drugs, semaglutide (Ozempic) and tirzepatide (Mounjaro), not only promote weight loss but also significantly reduce the risk of heart attacks and strokes in patients with type 2 diabetes. Using real-world insurance data, the study found up to an 18% reduction in major cardiovascular events, confirming powerful heart-protective effects that appear to extend beyond weight control.
New research indicates Ozempic and Mounjaro offer significant cardiovascular benefits beyond weight loss and blood sugar control. A real-world study...
New research indicates Ozempic and Mounjaro offer significant cardiovascular benefits beyond weight loss and blood sugar control. A real-world study...
For The Union-Tribune GLP one less for the road Apart from their widely celebrated effect at weight loss and diabetes management, GLP-1 drugs like...
New research is shedding light on how weight-loss and diabetes medications like Ozempic, Wegovy, and Mounjaro affect not only appetite but also the...
New research is shedding light on how weight-loss and diabetes medications like Ozempic, Wegovy, and Mounjaro affect not only appetite but also the...
Public interest in GLP‑1 receptor agonists has exploded in recent years. These medicines, known as GLP‑1 RAs, include drugs like semaglutide,...
TUESDAY, Nov. 25, 2025 — Women who stop taking a GLP-1 weight loss/diabetes medication just prior to a pregnancy appear to be at higher odds for...
A new study from the University of California San Diego has found that popular diabetes and weight-loss medications might also help people with colon...
The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a number of brain diseases.
The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a number of brain diseases.